NexoBrid Den europeiske union - norsk - EMA (European Medicines Agency)

nexobrid

mediwound germany gmbh - proteolytic enzymes enriched in bromelain - debridement - preparater for behandling av sår og sår - nexobrid er indikert for fjerning av eschar hos voksne med dype partielle og fullverdige termiske forbrenninger.

Fluenz Den europeiske union - norsk - EMA (European Medicines Agency)

fluenz

medimmune llc - reassortant influensa-virus (levende svekket) av følgende belastninger:a/california/7/2009 (h1n1)pdm09 som belastning, a/victoria/361/2011 (h3n2) som belastning, b/massachusetts/2/2012 som belastning - influenza, human; immunization - vaksiner - profylakse av influensa hos individer 24 måneder til under 18 år. bruk av fluenz bør være basert på offisielle anbefalinger.

Pandemic influenza vaccine H5N1 AstraZeneca (previously Pandemic influenza vaccine H5N1 Medimmune) Den europeiske union - norsk - EMA (European Medicines Agency)

pandemic influenza vaccine h5n1 astrazeneca (previously pandemic influenza vaccine h5n1 medimmune)

astrazeneca ab - reassortant influensavirus (levende dempet) av følgende stamme: a / vietnam / 1203/2004 (h5n1) stamme - influensa, human - vaksiner - profylakse av influensa i en offisielt erklært pandemisk situasjon hos barn og ungdom fra 12 måneder til under 18 år. pandemisk influensa h5n1-vaksine astrazeneca skal være brukt i samsvar med offisielle veiledning.

Vyvgart Den europeiske union - norsk - EMA (European Medicines Agency)

vyvgart

argenx - efgartigimod alfa - myasthenia gravis - immunsuppressive - vyvgart is indicated as an add on to standard therapy for the treatment of adult patients with generalised myasthenia gravis (gmg) who are anti acetylcholine receptor (achr) antibody positive.

Melatonin AGB 5 mg Norge - norsk - Statens legemiddelverk

melatonin agb 5 mg

agb-pharma ab - melatonin - tablett - 5 mg

Melatonin AGB 1 mg Norge - norsk - Statens legemiddelverk

melatonin agb 1 mg

agb-pharma ab - melatonin - tablett - 1 mg

Melatonin AGB 2 mg Norge - norsk - Statens legemiddelverk

melatonin agb 2 mg

agb-pharma ab - melatonin - tablett - 2 mg

Melatonin AGB 3 mg Norge - norsk - Statens legemiddelverk

melatonin agb 3 mg

agb-pharma ab - melatonin - tablett - 3 mg

Melatonin AGB 4 mg Norge - norsk - Statens legemiddelverk

melatonin agb 4 mg

agb-pharma ab - melatonin - tablett - 4 mg

Libtayo Den europeiske union - norsk - EMA (European Medicines Agency)

libtayo

regeneron ireland designated activity company (dac) - cemiplimab - karsinom, squamous cell - antineoplastiske midler - cutaneous squamous cell carcinomalibtayo as monotherapy is indicated for the treatment of adult patients with metastatic or locally advanced cutaneous squamous cell carcinoma (mcscc or lacscc) who are not candidates for curative surgery or curative radiation. basal cell carcinomalibtayo as monotherapy is indicated for the treatment of adult patients with locally advanced or metastatic basal cell carcinoma (labcc or mbcc) who have progressed on or are intolerant to a hedgehog pathway inhibitor (hhi). non-small cell lung cancerlibtayo as monotherapy is indicated for the first-line treatment of adult patients with non-small cell lung cancer (nsclc) expressing pd-l1 (in ≥ 50% tumour cells), with no egfr, alk or ros1 aberrations, who have:locally advanced nsclc who are not candidates for definitive chemoradiation, ormetastatic nsclc. libtayo in combination with platinum‐based chemotherapy is indicated for the first‐line treatment of adult patients with nsclc expressing pd-l1 (in ≥ 1% of tumour cells), with no egfr, alk or ros1 aberrations, who have:locally advanced nsclc who are not candidates for definitive chemoradiation, ormetastatic nsclc. cervical cancerlibtayo as monotherapy is indicated for the treatment of adult patients with recurrent or metastatic cervical cancer and disease progression on or after platinum-based chemotherapy.